Year: 2021
Type: article
Study design: Observational Study
Abstract: The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38-1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80-3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.
Source: Nature Communications
Authors: Barak Mizrahi(Formal analysis, Investigation, Visualization, Writing – original draft), Roni Lotan(Conceptualization, Data curation, Investigation, Methodology, Writing – original draft), Nir Kalkstein(Formal analysis, Investigation), Asaf Peretz(Writing – review & editing), Galit Perez(Project administration, Writing – review & editing), Amir Ben-Tov(Writing – review & editing), Gabriel Chodick(Methodology, Writing – review & editing), Sivan Gazit(Conceptualization, Project administration, Supervision, Writing – original draft), Tal Patalon(Conceptualization, Project administration, Supervision, Writing – original draft, Writing – review & editing)
Institutions: Maccabi Healthcare Services, Tel Aviv University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,560
OpenAlex ID: W3209833474
